Top Markets
#1 Akedo Akedo +59.32%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.39%
#4 Velvet Velvet +43.06%
#5 Black Phoenix Black Phoenix +34.58%
#6 τemplar τemplar +22.94%
#7 Cap Cap +19.28%
#8 Ribbita by Virtuals Ribbita by Virtuals +17.53%
#9 Cross Cross +17.30%
#10 Bitway Bitway +15.59%
Coin of the day
Akedo Akedo
設定
言語
日本
通貨
USD
テーマ
Nutroganics, Inc. Nutroganics, Inc.

Nutroganics, Inc.

NUTTQ
株式のランク #38311
Nutroganics, Inc.'s primary business strategy involved acquiring and overseeing... Nutroganics, Inc.'s primary business strategy involved acquiring and overseeing profitable companies within the healthy lifestyle industry, focusing heavily on nutritional supplements and the natural and organic food markets. One of its key operational entities was Silverbow Honey Company, a subsidiary that handled the production, packaging, and sale of various honey products. These goods were supplied to food manufacturers and prominent national grocery chains, marketed under both the Silverbow brand and as private label offerings. The company was based in Bethesda, Maryland. However, a significant development occurred on October 14, 2016, when Nutroganics, Inc. and its affiliated organizations filed a voluntary petition for Chapter 7 liquidation with the US Bankruptcy Court for the District of Delaware.
株価
$0.00001
最終同期: 2025-05-07
時価総額
$1.07M
変化（1日）
0.00%
変化（1年）
0.00%
国
US
取引 Nutroganics, Inc. (NUTTQ)

カテゴリー

Healthcare
Nutroganics, Inc.（NUTTQ）の利益
2026 時点の利益 TTM: 0
Nutroganics, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Nutroganics, Inc. の利益の推移（2026 〜 2026）
各年末の利益
年 利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差 国
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
$1.35B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
- -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
- -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
- -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
$26.37M -
US